Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy.

Expansion of adipose tissue in the orbits is a key feature of Graves' ophthalmopathy. Recent evidence shows that orbital fibroblasts are committed to differentiate into adipocytes under appropriate stimuli. Rosiglitazone, an agonist of the nuclear hormone receptor, peroxisome proliferator-activated receptor gamma (PPARgamma) is able to induce both differentiation of orbital fibroblasts into mature adipocytes and expression of the TSH receptor (TSHr) gene. Several studies have suggested an important role of the high mobility group AT-hook 2 (HMGA2) gene in adipocytic cell growth and development. To investigate further the association between adipogenesis-related genes and orbital fibroblasts, we treated fibroblasts from Graves' ophthalmopathy (FGOs) and from normal orbital tissues with fenofibrate, a specific agonist for PPARalpha. We then evaluated the expression of the PPARalpha, PPARgamma2, HMGA2, leptin and TSHr genes before and after 24 h of fenofibrate treatment, using semiquantitative and real-time PCR. For up to 96 h after exposure to fenofibrate, FGOs differentiated into adipocytes. PPARalpha and PPARgamma2 were expressed more in FGOs than in normal cultures, whereas TSHr mRNA was detected only in FGOs. Expression of HMGA2 mRNA and protein was significantly increased in FGOs from 6 to 24 h after fenofibrate, confirming its role in the early phase of adipocyte differentiation. Treatment with fenofibrate for 24 h significantly increased the expression of leptin and TSHr genes. Moreover, TSH treatment significantly increased the accumulation of cAMP, demonstrating that FGOs express functional TSHr. The high level of expression of PPARalpha other than PPARgamma2 transcripts and the stimulating effect of fenofibrate on adipogenesis and on HMGA2, leptin and TSHr genes also indicate that the PPARalpha pathway plays an important part in the adipocyte differentiation of FGOs. These findings suggest that novel drugs to antagonize PPARalpha, other than the PPARgamma signalling system, may also need to be considered in the treatment or prevention of Graves' ophthalmopathy.

[1]  V. Colantuoni,et al.  All-trans retinoic acid- and N-(4-hydroxyphenil)-retinamide-induced growth arrest and apoptosis in orbital fibroblasts in Graves' disease. , 2003, Metabolism: clinical and experimental.

[2]  A. Bellastella,et al.  Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. , 2002, The Journal of clinical endocrinology and metabolism.

[3]  R. Bahn,et al.  Stimulation of adipogenesis, peroxisome proliferator-activated receptor-γ (PPARγ), and thyrotropin receptor by PPARγ agonist in human orbital preadipocyte fibroblasts , 2002 .

[4]  Terry J. Smith.  Orbital fibroblasts exhibit a novel pattern of responses to proinflammatory cytokines: potential basis for the pathogenesis of thyroid-associated ophthalmopathy. , 2002, Thyroid : official journal of the American Thyroid Association.

[5]  R. Glazer,et al.  Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. , 2002, Molecular cancer therapeutics.

[6]  M. Nikiforova,et al.  Establishment of a non‐tumorigenic papillary thyroid cell line (FB‐2) carrying the RET/PTC1 rearrangement , 2002, International journal of cancer.

[7]  C. Dani,et al.  Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. , 2002, The Biochemical journal.

[8]  Terry J. Smith,et al.  Fibroblast subsets in the human orbit: Thy‐1+ and Thy‐1‐ subpopulations exhibit distinct phenotypes , 2002, European journal of immunology.

[9]  B. Staels,et al.  Peroxisome proliferator-activated receptors in inflammation control. , 2001, The Journal of endocrinology.

[10]  A. Bellastella,et al.  Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. , 2000, Journal of molecular endocrinology.

[11]  G. Chiappetta,et al.  A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. , 2000, Cancer genetics and cytogenetics.

[12]  Santa Jeremy Ono,et al.  Transgenic Mice Expressing a Truncated Form of the High Mobility Group I-C Protein Develop Adiposity and an Abnormally High Prevalence of Lipomas* , 2000, The Journal of Biological Chemistry.

[13]  K. Chada,et al.  In vivo modulation of Hmgic reduces obesity , 2000, Nature Genetics.

[14]  C. Croce,et al.  The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. , 1999, Cancer research.

[15]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[16]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[17]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[18]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[19]  V. Colantuoni,et al.  Changes in tissue transglutaminase activity and expression during retinoic acid-induced growth arrest and apoptosis in primary cultures of human epithelial prostate cells. , 1999, The Journal of clinical endocrinology and metabolism.

[20]  S. Woods,et al.  Signals that regulate food intake and energy homeostasis. , 1998, Science.

[21]  C. Spitzweg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Thyrotropin Receptor Expression in Graves ’ Orbital Adipose/Connective Tissues: Potential Autoantigen in , 2022 .

[22]  A. Fusco,et al.  Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. , 1998, Cancer research.

[23]  M. Lazar,et al.  Peroxisome Proliferator Activated Receptor γ, CCAAT/ Enhancer-binding Protein α, and Cell Cycle Status Regulate the Commitment to Adipocyte Differentiation* , 1997, The Journal of Biological Chemistry.

[24]  A. Sorisky,et al.  Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. , 1996, The Journal of clinical endocrinology and metabolism.

[25]  G. Viglietto,et al.  Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. , 1996, Cancer research.

[26]  Dimitris Thanos,et al.  Reversal of intrinsic DNA bends in the IFNβ gene enhancer by transcription factors and the architectural protein HMG I(Y) , 1995, Cell.

[27]  Xianjin Zhou,et al.  Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C , 1995, Nature.

[28]  G. Chiappetta,et al.  The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. , 1995, Oncogene.

[29]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[30]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1994, Nature.

[31]  A. Porcellini,et al.  Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue , 1993, The Lancet.

[32]  P. Cary,et al.  cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. , 1991, Nucleic acids research.

[33]  R. Reeves,et al.  Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y , 1989, Molecular and cellular biology.

[34]  J. Bar-Tana,et al.  Adipose conversion of cultured rat primary preadipocytes by hypolipidemic drugs. , 1986, Biochimica et biophysica acta.

[35]  M. Evans,et al.  Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use? , 2003, The Journal of clinical endocrinology and metabolism.

[36]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.

[37]  B. Spiegelman,et al.  PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. , 1999, Molecular cell.

[38]  S. Aizawa,et al.  PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. , 1999, Molecular cell.

[39]  M. Lazar,et al.  Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. , 1997, The Journal of biological chemistry.

[40]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[41]  S. Advani,et al.  All trans retinoic acid. , 1995, The Journal of the Association of Physicians of India.

[42]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. , 1994, Cell.

[43]  K. Emerson.  Endocrinology and metabolism. , 1952, Medicine of the year.